MANE
Veradermics, Incorporated
Price Chart
Latest Quote
$117.29
+13.69 (+13.21%)
Current Price
| Previous Close | $103.60 |
| Open | $104.38 |
| Day High | $118.63 |
| Day Low | $102.87 |
| Volume | 1,039,822 |
Stock Information
| Shares Outstanding | 41.78M |
| Cash Equivalents | $390.80M |
| Net Income | $-98.80M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.90B |
| EPS (TTM) | $-2.65 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.78B |
| Income | $-98.80M |
| Book/sh | $10.46 |
| Cash/sh | $9.35 |
| Employees | 24 |
Financial Ratios
| Quick Ratio | 58.44 |
| Current Ratio | 59.12 |
| Debt/Eq | 0.00 |
Returns & Margins
Ownership
| Insider Ownership | 2.74% |
| Institutional Ownership | 79.81% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -38.61 |
| P/B | 11.21 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $132.80 |
Technical Indicators
| SMA20 | $97.98 |
| SMA50 | $96.27 |
| RSI | 67.45 |
| ATR | 7.9800 |
| Shares Float | 27.21M |
| Short Float | 8.69% |
| Short Ratio | 3.76 |
| Rel Volume | 1.91 |
Performance History
| Week | +28.96% |
| Month | +15.42% |
| Quarter | +84.74% |
| YTD | +210.70% |
| 10 Years | +210.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $117.29 | 1,055,100 |
| 2026-06-23 | $103.60 | 616,500 |
| 2026-06-22 | $102.79 | 896,800 |
| 2026-06-18 | $93.87 | 826,600 |
| 2026-06-17 | $91.87 | 415,300 |
| 2026-06-16 | $90.95 | 513,600 |
| 2026-06-15 | $96.27 | 305,100 |
| 2026-06-12 | $96.07 | 260,400 |
| 2026-06-11 | $94.40 | 206,500 |
| 2026-06-10 | $92.98 | 399,500 |
| 2026-06-09 | $95.91 | 494,300 |
| 2026-06-08 | $90.32 | 425,700 |
| 2026-06-05 | $91.69 | 548,800 |
| 2026-06-04 | $101.23 | 439,800 |
| 2026-06-03 | $96.74 | 579,100 |
| 2026-06-02 | $98.18 | 428,400 |
| 2026-06-01 | $101.51 | 510,400 |
| 2026-05-29 | $100.91 | 1,189,600 |
| 2026-05-28 | $102.88 | 486,800 |
| 2026-05-27 | $100.13 | 471,700 |
| 2026-05-26 | $102.50 | 573,400 |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
đ° Latest News
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
Zacks âĸ 2026-06-24T13:55:01Z
Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-19T16:24:51Z
Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts
Simply Wall St. âĸ 2026-05-21T06:09:37Z
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026
Insider Monkey âĸ 2026-05-21T03:02:27Z
The IPO Boom Isnât in Tech and AIâYet
Barrons.com âĸ 2026-05-15T08:52:00Z
Citi Remains Bullish on Veradermics, Incorporated (MANE)
Insider Monkey âĸ 2026-05-10T23:12:27Z
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill
MarketBeat âĸ 2026-05-03T16:02:11Z
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01
Insider Monkey âĸ 2026-04-30T13:57:51Z
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
Benzinga âĸ 2026-04-29T09:46:09Z
Midday Fly By: Verizon reports âbeat and raise,â Shell to acquire ARC
TipRanks âĸ 2026-04-28T00:01:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Interest Expense | $0 | $585,000 | $36,000 |
| Total Expenses | $71,557,000 | $26,384,000 | $17,324,000 |
| Net Non Operating Interest Income Expense | $1,562,000 | $-104,000 | $834,000 |
| Interest Expense Non Operating | $0 | $585,000 | $36,000 |
| Operating Expense | $71,557,000 | $26,384,000 | $17,324,000 |
| Other Operating Expenses | $-790,000 | $-394,000 | - |
| General And Administrative Expense | $10,282,000 | $3,495,000 | $2,353,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Net Interest Income | $1,562,000 | $-104,000 | $834,000 |
| Interest Income | $1,562,000 | $481,000 | $870,000 |
| Normalized Income | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Net Income From Continuing And Discontinued Operation | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Total Operating Income As Reported | $-72,347,000 | $-26,778,000 | $-17,324,000 |
| Net Income Common Stockholders | $-83,373,000 | $-27,303,000 | $-16,490,000 |
| Net Income | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Net Income Including Noncontrolling Interests | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Net Income Continuous Operations | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Pretax Income | $-69,995,000 | $-26,488,000 | $-16,490,000 |
| Interest Income Non Operating | $1,562,000 | $481,000 | $870,000 |
| Operating Income | $-71,557,000 | $-26,384,000 | $-17,324,000 |
| Per Share | |||
| Diluted EPS | $-2.00 | $-1.37 | $-1.51 |
| Basic EPS | $-2.00 | $-1.37 | $-1.51 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-69,995,000 | $-25,903,000 | $-16,454,000 |
| EBITDA (Bullshit earnings) | $-69,995,000 | $-25,903,000 | $-16,454,000 |
| EBIT | $-69,995,000 | $-25,903,000 | $-16,454,000 |
| Diluted Average Shares | $35,077,084 | $19,906,853 | $13,804,188 |
| Basic Average Shares | $35,077,084 | $19,906,853 | $13,804,188 |
| Diluted NI Availto Com Stockholders | $-83,373,000 | $-27,303,000 | $-16,490,000 |
| Preferred Stock Dividends | $13,378,000 | $815,000 | - |
| Tax Provision | $0 | $0 | $0 |
| Research And Development | $62,065,000 | $23,283,000 | $14,971,000 |
| Selling General And Administration | $10,282,000 | $3,495,000 | $2,353,000 |
| Other Gand A | $10,282,000 | $3,495,000 | $2,353,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-121,014,000 | $-48,480,000 | $-22,242,000 |
| Total Assets | $152,619,000 | $55,535,000 | $17,562,000 |
| Total Non Current Assets | $125,000 | $0 | $0 |
| Current Assets | $152,494,000 | $55,535,000 | $17,562,000 |
| Other Current Assets | $381,000 | $38,000 | $46,000 |
| Current Deferred Assets | $3,387,000 | $0 | - |
| Prepaid Assets | $5,609,000 | $1,038,000 | $1,220,000 |
| Receivables | $1,255,000 | $1,375,000 | $0 |
| Taxes Receivable | $1,255,000 | $1,375,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $141,862,000 | $53,084,000 | $16,296,000 |
| Cash And Cash Equivalents | $21,766,000 | $53,084,000 | $16,296,000 |
| Debt | |||
| Total Debt | $4,000 | $0 | $786,000 |
| Long Term Debt And Capital Lease Obligation | $4,000 | $0 | $786,000 |
| Long Term Debt | - | - | $786,000 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $273,633,000 | $104,015,000 | $39,804,000 |
| Total Non Current Liabilities Net Minority Interest | $264,481,000 | $99,297,000 | $36,752,000 |
| Current Liabilities | $9,152,000 | $4,718,000 | $3,052,000 |
| Other Current Liabilities | $47,000 | - | - |
| Payables And Accrued Expenses | $9,105,000 | $4,718,000 | $3,052,000 |
| Payables | $2,126,000 | $2,248,000 | $1,852,000 |
| Accounts Payable | $2,126,000 | $2,248,000 | $1,852,000 |
| Equity | |||
| Common Stock Equity | $-121,014,000 | $-48,480,000 | $-22,242,000 |
| Total Equity Gross Minority Interest | $-121,014,000 | $-48,480,000 | $-22,242,000 |
| Stockholders Equity | $-121,014,000 | $-48,480,000 | $-22,242,000 |
| Gains Losses Not Affecting Retained Earnings | $60,000 | $0 | - |
| Other Equity Adjustments | $60,000 | - | - |
| Retained Earnings | $-123,421,000 | $-49,231,000 | $-22,743,000 |
| Preferred Securities Outside Stock Equity | $264,477,000 | $99,297,000 | $35,966,000 |
| Other | |||
| Ordinary Shares Number | $37,340,290 | $35,077,084 | $35,077,084 |
| Share Issued | $37,340,290 | $35,077,084 | $35,077,084 |
| Tangible Book Value | $-121,014,000 | $-48,480,000 | $-22,242,000 |
| Invested Capital | $-121,014,000 | $-48,480,000 | $-21,456,000 |
| Working Capital | $143,342,000 | $50,817,000 | $14,510,000 |
| Capital Lease Obligations | $4,000 | $0 | - |
| Total Capitalization | $-121,014,000 | $-48,480,000 | $-21,456,000 |
| Additional Paid In Capital | $2,346,000 | $750,000 | $500,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $4,000 | $0 | - |
| Current Accrued Expenses | $6,979,000 | $2,470,000 | $1,200,000 |
| Net PPE | $125,000 | $0 | - |
| Gross PPE | $125,000 | $0 | - |
| Other Properties | $125,000 | - | - |
| Other Short Term Investments | $120,096,000 | $0 | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-71,626,000 | $-23,688,000 | $-13,510,000 |
| Operating Activities | |||
| Operating Cash Flow | $-71,602,000 | $-23,688,000 | $-13,510,000 |
| Cash Flow From Continuing Operating Activities | $-71,602,000 | $-23,688,000 | $-13,510,000 |
| Investing Activities | |||
| Capital Expenditure | $-24,000 | - | - |
| Investing Cash Flow | $-118,858,000 | $0 | - |
| Cash Flow From Continuing Investing Activities | $-118,858,000 | $0 | - |
| Financing Activities | |||
| Issuance Of Capital Stock | $159,433,000 | $53,097,000 | $13,930,000 |
| Financing Cash Flow | $159,142,000 | $60,476,000 | $13,895,000 |
| Cash Flow From Continuing Financing Activities | $159,142,000 | $60,476,000 | $13,895,000 |
| Net Other Financing Charges | $-447,000 | $-283,000 | $-35,000 |
| Net Preferred Stock Issuance | $159,433,000 | $53,097,000 | $13,930,000 |
| Preferred Stock Issuance | $159,433,000 | $53,097,000 | $13,930,000 |
| Other | |||
| Repayment Of Debt | $0 | $-845,000 | $0 |
| Issuance Of Debt | $0 | $8,507,000 | $0 |
| Interest Paid Supplemental Data | $0 | $95,000 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $21,766,000 | $53,084,000 | $16,296,000 |
| Beginning Cash Position | $53,084,000 | $16,296,000 | $15,911,000 |
| Changes In Cash | $-31,318,000 | $36,788,000 | $385,000 |
| Proceeds From Stock Option Exercised | $156,000 | $0 | - |
| Net Issuance Payments Of Debt | $0 | $7,662,000 | $0 |
| Net Long Term Debt Issuance | $0 | $7,662,000 | $0 |
| Long Term Debt Payments | $0 | $-845,000 | $0 |
| Long Term Debt Issuance | $0 | $8,507,000 | $0 |
| Net Investment Purchase And Sale | $-118,834,000 | $0 | - |
| Sale Of Investment | $25,018,000 | $0 | - |
| Purchase Of Investment | $-143,852,000 | $0 | - |
| Net PPE Purchase And Sale | $-24,000 | $0 | - |
| Purchase Of PPE | $-24,000 | $0 | - |
| Change In Working Capital | $-3,886,000 | $732,000 | $920,000 |
| Change In Other Current Liabilities | $-39,000 | $0 | - |
| Change In Payables And Accrued Expense | $4,388,000 | $1,917,000 | $1,903,000 |
| Change In Accrued Expense | $4,510,000 | $1,271,000 | $549,000 |
| Change In Payable | $-122,000 | $646,000 | $1,354,000 |
| Change In Account Payable | $-122,000 | $646,000 | $1,354,000 |
| Change In Prepaid Assets | $-8,235,000 | $-1,185,000 | $-983,000 |
| Other Non Cash Items | $839,000 | $1,818,000 | $1,854,000 |
| Stock Based Compensation | $1,440,000 | $250,000 | $206,000 |
| Net Income From Continuing Operations | $-69,995,000 | $-26,488,000 | $-16,490,000 |
Fetched: 2026-06-21